Neumora Therapeutics Inc (NMRA) 뉴스

Form 8-K - Current report

Neumora Therapeutics Announces Leadership Transition

Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman...

Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact The...

Form 8-K - Current report

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA

The DJS Law Group announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”...

Form 8-K - Current report

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and...

Neumora Therapeutics to Participate in Upcoming Conferences in November

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities